{"id":"https://openalex.org/W4282940586","doi":"https://doi.org/10.1158/1538-7445.am2022-5422","title":"Abstract 5422: Exploring the feasibility of longer dosing intervals in a population with relapsed/refractory classic Hodgkin's lymphoma based on population pharmacokinetics modeling analysis","display_name":"Abstract 5422: Exploring the feasibility of longer dosing intervals in a population with relapsed/refractory classic Hodgkin's lymphoma based on population pharmacokinetics modeling analysis","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282940586","doi":"https://doi.org/10.1158/1538-7445.am2022-5422"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-5422","doi":"https://doi.org/10.1158/1538-7445.am2022-5422","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-5422","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067523140","display_name":"Benchao Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benchao Chen","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103911123","display_name":"Yongcheng Dong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yongcheng Dong","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jin Xiao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin Xiao","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020895830","display_name":"Max Mu Wang","orcid":"https://orcid.org/0000-0002-2810-8561","observed_orcids":["https://orcid.org/0000-0002-2810-8561"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Max Wang","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109525626","display_name":"Dennis Xia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennis Xia","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075723177","display_name":"Michelle Xia","orcid":"https://orcid.org/0000-0002-5137-2002","observed_orcids":["https://orcid.org/0000-0002-5137-2002"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michelle Xia","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074582238","display_name":"Baiyong Li","orcid":"https://orcid.org/0009-0002-2426-9656","observed_orcids":["https://orcid.org/0009-0002-2426-9656"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Baiyong Li","raw_affiliation_strings":["1Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"5422","last_page":"5422"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.5015000104904175,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.5015000104904175,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.28859999775886536,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.047600001096725464,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/penpulimab","display_name":"penpulimab","score":1.0},{"id":"https://openalex.org/keywords/extended-dosing-interval","display_name":"extended dosing interval","score":0.8650000095367432},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.7559999823570251},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.781000018119812},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6899999976158142},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6970000267028809},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.6230000257492065},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.3179999887943268},{"id":"https://openalex.org/keywords/two-compartment-model","display_name":"two-compartment model","score":0.6430000066757202},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.5479999780654907}],"concepts":[{"id":"https://openalex.org/C2778335254","wikidata":"https://www.wikidata.org/wiki/Q5137314","display_name":"Cmin","level":4,"score":0.9344462156295776},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7907764315605164},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7387040257453918},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.7197967767715454},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6319401860237122},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5965036153793335},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5799246430397034},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5507708787918091},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4295375645160675},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42228081822395325},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-5422","doi":"https://doi.org/10.1158/1538-7445.am2022-5422","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-5422","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3215150952","https://openalex.org/W3212885064","https://openalex.org/W3167228154","https://openalex.org/W4308398376","https://openalex.org/W4415507158","https://openalex.org/W4284713527","https://openalex.org/W2895957341","https://openalex.org/W2891290839","https://openalex.org/W2142492861","https://openalex.org/W7131222438"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Penpulimab":[2,48],"is":[3,262],"a":[4,52,60,94,119,246,468],"humanized":[5],"IgG1":[6],"monoclonal":[7],"antibody":[8],"that":[9,320,417],"blocks":[10],"PD-1":[11],"binding":[12],"to":[13,82,190,338,434],"PD-L1.":[14],"During":[15],"the":[16,26,91,194,203,260,280,321,339,344,367,372,388,461,485],"dose-escalation":[17],"phase,":[18],"no":[19],"dose-limiting":[20],"toxicity":[21],"event":[22,178],"was":[23,30,49,112,145,200,245,301],"observed,":[24],"and":[25,42,67,80,85,101,134,162,212,221,285,287,306,351,359,385,406,411,430,442],"maximum":[27],"administered":[28,50],"dose(MAD)":[29],"10":[31],"mg/kg":[32,44,331,397],"Q2W.":[33],"The":[34,128,151,238,316,383,400],"RO%":[35],"of":[36,93,121,226,257,314,347,369,371,463,484],"all":[37,193],"dose":[38,269],"groups":[39],"(1.0,":[40],"3.0":[41],"10.0":[43],"Q2W)":[45,58],"reached":[46],"80%~100%.":[47],"in":[51,59,69,136,167,192,222,235,270,294,309,364,467],"fixed":[53,268,404],"dosing":[54,74,96,405,465],"regimen":[55,97,392],"(200":[56,98,209],"mg":[57,99,103,210,214,218,327,341,349,353,390,420,424,436],"phase":[61],"II":[62],"study":[63],"(AK105-201)":[64],"demonstrating":[65],"efficacy":[66,152,281,429],"safety":[68,307,431],"R/R":[70,295],"cHL":[71,296],"patients.":[72,297],"Longer":[73],"intervals":[75,466],"may":[76],"offer":[77,427],"greater":[78,440],"flexibility":[79,441],"convenience":[81],"both":[83,365,418],"patients":[84,310],"healthcare":[86],"professionals.":[87],"So":[88],"we":[89],"explored":[90],"feasibility":[92,462],"longer":[95,464],"Q3W":[100,211,350,421],"400":[102,213,352,389,423],"Q6W).":[104],"Methods:":[105],"A":[106],"penpulimab":[107,244],"population":[108,373,469,477],"PK":[109,116,130,198,288,304,317,414],"(PPK)":[110],"model":[111,205,242,248],"established":[113],"based":[114,475],"on":[115,476],"data":[117],"from":[118,124],"total":[120],"332":[122],"subjects":[123],"six":[125,195],"clinical":[126,196],"studies.":[127,197,272],"following":[129],"parameters":[131],"were":[132,277,334,356,374,393],"determined":[133],"used":[135],"subsequent":[137,271],"analyses:":[138],"Cmin,ss,":[139,292],"Cmax,ss,":[140,291],"AUCss.":[141],"Exposure-response":[142],"(ER)":[143],"evaluation":[144],"conducted":[146,201,401],"using":[147,202],"univariate":[148],"logistic":[149],"regression.":[150],"endpoints":[153,171,282],"included":[154,172],"complete":[155],"response":[156,159,308],"(CR),":[157],"overall":[158],"rate":[160,165],"(ORR)":[161],"disease":[163],"control":[164],"(DCR)":[166],"AK105-201":[168],"study.":[169],"Safety":[170],"grade":[173,180],"\u2265":[174,181],"3":[175,182,227,330,377],"treatment-related":[176],"adverse":[177,184],"(TRAE),":[179],"immune-related":[183],"events":[185],"(irAE),":[186],"or":[187,329,422],"AE":[188],"leading":[189],"suspension":[191],"simulation":[199,318],"PPK":[204,240],"among":[206],"different":[207,312],"regimens":[208,355],"Q6W":[215,354,391],"vs.":[216],"200":[217,326,340,348,419,435],"Q2w":[219],"regimen),":[220],"comparison":[223],"with":[224,249,255,311,470],"Cmin,ss":[225,346,368],"\u03bcg/mL":[228],"(6":[229],"x":[230],"concentration":[231],"for":[232,243,325,488],"80%":[233],"RO":[234],"vitro).":[236],"Result:":[237],"final":[239],"structural":[241],"two-compartment":[247],"first-order":[250],"elimination.":[251],"Body":[252],"weight":[253],"correlated":[254],"volume":[256],"distribution":[258],"but":[259],"effect":[261],"not":[263],"considered":[264],"clinically":[265],"significant,":[266],"supporting":[267],"Relatively":[273],"flat":[274,409],"ER":[275],"relationships":[276],"observed":[278,302],"betwedn":[279],"(CR,":[283],"ORR":[284],"DCR)":[286],"exposure":[289,305],"(simulated":[290],"AUCss)":[293],"No":[298],"apparent":[299],"correlation":[300],"between":[303],"types":[313],"cancer.":[315],"showed":[319,407],"steady-state":[322],"concentration-time":[323],"curves":[324],"Q2W":[328,332,342],"administration":[333],"generally":[335],"consistent.":[336],"Compared":[337],"regimen,":[343],"mean":[345],"approximately":[357],"36.5%":[358],"55.5%":[360],"lower,":[361],"respectively.":[362],"But":[363],"cases,":[366],"97.5%":[370],"higher":[375],"than":[376,395],"\u03bcg/mL,":[378],"suggesting":[379],"sufficient":[380],"receptor":[381],"occupancy.":[382],"Cmax,ss":[384],"AUCss":[386],"under":[387],"lower":[394],"MAD(10":[396],"Q2W).":[398],"Conclusions:":[399],"analyses":[402],"support":[403],"relatively":[408],"exposure-efficacy":[410],"exposure-safety":[412],"relationships.":[413],"simulations":[415],"suggest":[416],"Q6w":[425],"could":[426],"similar":[428],"as":[432],"compared":[433],"Q2W,":[437],"while":[438],"allow":[439],"convenience.":[443],"Citation":[444],"Format:":[445],"Benchao":[446],"Chen,":[447],"Yongcheng":[448],"Dong,":[449],"Jin":[450],"Xiao,":[451],"Max":[452],"Wang,":[453],"Dennis":[454],"Xia,":[455,457],"Michelle":[456],"Baiyong":[458],"Li.":[459],"Exploring":[460],"relapsed/refractory":[471],"classic":[472],"Hodgkin's":[473],"lymphoma":[474],"pharmacokinetics":[478],"modeling":[479],"analysis":[480],"[abstract].":[481],"In:":[482],"Proceedings":[483],"American":[486],"Association":[487],"Cancer":[489,500],"Research":[490],"Annual":[491],"Meeting":[492],"2022;":[493],"2022":[494],"Apr":[495],"8-13.":[496],"Philadelphia":[497],"(PA):":[498],"AACR;":[499],"Res":[501],"2022;82(12_Suppl):Abstract":[502],"nr":[503],"5422.":[504]},"counts_by_year":[],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2022-06-16T00:00:00"}